152 related articles for article (PubMed ID: 36039519)
1. Single-center Evaluation of Safety & Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Solid Organ Transplantation.
Sweiss H; Hall R; Zeilmann D; Escamilla J; Bhayana S; Patel R; Long C
Prog Transplant; 2022 Dec; 32(4):357-362. PubMed ID: 36039519
[No Abstract] [Full Text] [Related]
2. Glucagon-like Peptide 1 Receptor Agonists and Cardiovascular Outcomes in Solid Organ Transplant Recipients With Diabetes Mellitus.
Dotan I; Rudman Y; Turjeman A; Akirov A; Steinmetz T; Calvarysky B; Diker Cohen T
Transplantation; 2024 Jul; 108(7):e121-e128. PubMed ID: 38361246
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Solid Organ Transplant Recipients.
Sweiss H; Selznick L; Contreras J; Long C; Hall R; Bhayana S; Patel R; Klein K
Prog Transplant; 2023 Sep; 33(3):261-265. PubMed ID: 37491859
[No Abstract] [Full Text] [Related]
4. Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.
Gorgojo-Martínez JJ; Serrano-Moreno C; Sanz-Velasco A; Feo-Ortega G; Almodóvar-Ruiz F
Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):129-137. PubMed ID: 28077257
[TBL] [Abstract][Full Text] [Related]
5. Impact of Initiating a GLP1 Agonist and/or SGLT2 Inhibitor Therapy on De-Escalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team.
Champion M; Wills Avila G; Garcia AE; Álvarez Delgado FM; Valdez CA
J Prim Care Community Health; 2024; 15():21501319241231398. PubMed ID: 38353180
[TBL] [Abstract][Full Text] [Related]
6. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen.
Davies ML; Pham DQ; Drab SR
Pharmacotherapy; 2016 Aug; 36(8):893-905. PubMed ID: 27340935
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes.
Al-Ozairi E; Irshad M; Taghadom E; Sojan L; Al Kandari J; Alroudhan D; le Roux CW
Obesity (Silver Spring); 2023 Mar; 31(3):716-723. PubMed ID: 36811241
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes.
Ng E; Shaw JE; Wood A; Maple-Brown LJ; Hare MJ
Aust J Gen Pract; 2022 Jul; 51(7):513-518. PubMed ID: 35773162
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes.
Di Dalmazi G; Coluzzi S; Baldassarre MPA; Ghit A; Graziano G; Rossi MC; Ciappini B; Milo M; Carrieri F; Nicolucci A; Consoli A; Formoso G
Front Endocrinol (Lausanne); 2022; 13():892702. PubMed ID: 35909534
[TBL] [Abstract][Full Text] [Related]
10. Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
Takeshita Y; Kita Y; Tanaka T; Goto H; Nakano Y; Teramura C; Enyama Y; Takamura T;
J Diabetes Investig; 2022 Jun; 13(6):965-974. PubMed ID: 35034428
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
12. Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.
Kalra S; Kalhan A; Berard L
Postgrad Med; 2020 Nov; 132(8):663-666. PubMed ID: 32781867
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
[TBL] [Abstract][Full Text] [Related]
15. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
16. The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 Diabetes.
Boye KS; Mody R; Lage MJ; Malik RE
Clin Ther; 2020 Sep; 42(9):1812-1817.e2. PubMed ID: 32741645
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?
Albert SG; Wood EM; Ahir V
Diabetes Metab Syndr; 2023 Jan; 17(1):102696. PubMed ID: 36596264
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
Berra CC; Resi V; Mirani M; Folini L; Rossi A; Solerte SB; Fiorina P
Pharmacol Res; 2020 Sep; 159():104996. PubMed ID: 32574827
[TBL] [Abstract][Full Text] [Related]
19. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services.
Dao K; Shechtman S; Weber-Schoendorfer C; Diav-Citrin O; Murad RH; Berlin M; Hazan A; Richardson JL; Eleftheriou G; Rousson V; Diezi L; Haefliger D; Simões-Wüst AP; Addor MC; Baud D; Lamine F; Panchaud A; Buclin T; Girardin FR; Winterfeld U
BMJ Open; 2024 Apr; 14(4):e083550. PubMed ID: 38663923
[TBL] [Abstract][Full Text] [Related]
20. GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice.
Díaz-Trastoy O; Villar-Taibo R; Sifontes-Dubón M; Mozo-Peñalver H; Bernabeu-Morón I; Cabezas-Agrícola JM; Muñoz-Leira V; Peinó-García R; Martís-Sueiro A; García-López JM; Martínez-Olmos MA
Clin Ther; 2020 Feb; 42(2):e1-e12. PubMed ID: 32005534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
